Cancer Clinical Trials
Current and Controversial
Issues in Design and Analysis
Chapman & Hall/CRC Biostatistics Series
Editor-in-Chief
Shein-Chung Chow, Ph.D., Professor, Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina
Series Editors
Byron Jones, Biometrical Fellow, Statistical Methodology, Integrated Information Sciences, Novartis Pharma AG, Basel, Switzerland
Jen-pei Liu, Professor, Division of Biometry, Department of Agronomy, National Taiwan University, Taipei, Taiwan
Karl E. Peace, Georgia Cancer Coalition, Distinguished Cancer Scholar, Senior Research Scientist and Professor of Biostatistics, Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro, Georgia
Bruce W. Turnbull, Professor, School of Operations Research and Industrial Engineering, Cornell University, Ithaca, New York
Published Titles
Adaptive Design Methods in Clinical Trials, Second Edition
Shein-Chung Chow and Mark Chang
Adaptive Designs for Sequential Treatment Allocation
Alessandro Baldi Antognini and Alessandra Giovagnoli
Adaptive Design Theory and Implementation Using SAS and R, Second Edition
Mark Chang
Advanced Bayesian Methods for Medical Test Accuracy
Lyle D. Broemeling
Advances in Clinical Trial Biostatistics
Nancy L. Geller
Applied Meta-Analysis with R
Ding-Geng (Din) Chen and Karl E. Peace
Basic Statistics and Pharmaceutical Statistical Applications, Second Edition
James E. De Muth
Bayesian Adaptive Methods for Clinical Trials
Scott M. Berry, Bradley P. Carlin, J. Jack Lee, and Peter Muller
Bayesian Analysis Made Simple: An Excel GUI for WinBUGS
Phil Woodward
Bayesian Methods for Measures of Agreement
Lyle D. Broemeling
Bayesian Methods for Repeated Measures
Lyle D. Broemeling
Bayesian Methods in Epidemiology
Lyle D. Broemeling
Bayesian Methods in Health Economics
Gianluca Baio
Bayesian Missing Data Problems: EM, Data Augmentation and Noniterative Computation
Ming T. Tan, Guo-Liang Tian, and Kai Wang Ng
Bayesian Modeling in Bioinformatics
Dipak K. Dey, Samiran Ghosh, and Bani K. Mallick
Benefit-Risk Assessment in Pharmaceutical Research and Development
Andreas Sashegyi, James Felli, and Rebecca Noel
Benefit-Risk Assessment Methods in Medical Product Development: Bridging Qualitative and Quantitative Assessments
Qi Jiang and Weili He
Biosimilars: Design and Analysis of Follow-on Biologics
Shein-Chung Chow
Chapman & Hall/CRC Biostatistics Series
Cancer Clinical Trials
Current and Controversial
Issues in Design and Analysis
Edited by
Stephen L. George
Duke University School of Medicine
Durham, North Carolina, USA
Xiaofei Wang
Duke University School of Medicine
Durham, North Carolina, USA
Herbert Pang
The University of Hong Kong
Hong Kong, China
Contents
Landmarks
CRC Press
Taylor & Francis Group
6000 Broken Sound Parkway NW, Suite 300
Boca Raton, FL 33487-2742
2016 by Taylor & Francis Group, LLC
CRC Press is an imprint of Taylor & Francis Group, an Informa business
No claim to original U.S. Government works
Printed on acid-free paper
Version Date: 20160414
International Standard Book Number-13: 978-1-4987-0688-9 (Hardback)
This book contains information obtained from authentic and highly regarded sources. Reasonable efforts have been made to publish reliable data and information, but the author and publisher cannot assume responsibility for the validity of all materials or the consequences of their use. The authors and publishers have attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint.
Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers.
For permission to photocopy or use material electronically from this work, please access www.copyright.com (http://www.copyright.com/) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.
Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.
Visit the Taylor & Francis Web site at
http://www.taylorandfrancis.com
and the CRC Press Web site at
http://www.crcpress.com
To Ed Gehan and Marvin Zelen, who early in my
career taught me much about the art and science of
cancer biostatistics and served as role models while
doing so.
Stephen L. George
To my beloved family and in memory of my father.
Xiaofei Wang
To my parents and mentors at Duke, the CALGB, and
the Alliance for their support and guidance in my
quest for knowledge in the field of cancer clinical trials.
Herbert Pang
Contents
Stephen L. George, Xiaofei Wang, and Herbert Pang
Simon Wandel, Heinz Schmidli, and Beat Neuenschwander
Dong Xi, Ekkehard Glimm, and Frank Bretz
Steven Snapinn and Qi Jiang
Michael C. Sachs and Lisa M. McShane
Mark R. Conaway and Nolan A. Wages
Sin-Ho Jung
Edward Lakatos
Rajeshwari Sridhara and Thomas Gwise
Diane Fairclough
Edward L. Korn and Boris Freidlin
J. Jack Lee and Lorenzo Trippa
Marie Davidian, Anastasios (Butch) Tsiatis, and Eric Laber
There are many important and controversial topics in the design and analysis of cancer clinical trials, including adaptive approaches, biomarker-based trials, and dynamic treatment regime trials. This book provides readers with a current understanding of the critical issues in these and other topics with state-of-the-art approaches. Each chapter is written by well-known statisticians from academic institutions, regulatory agencies (FDA), the National Cancer Institute, or the pharmaceutical industry, all with extensive experience in cancer clinical trials. Examples are taken from actual cancer clinical trials. The topics covered are:
Next page